How effective is Amivantamab in treating lung cancer?

Amivantamab (Amivantamab) is a new type of targeted therapy for the treatment of specific subtypes of non-small cell lung cancer (NSCLC), including EGFR Patients with gene mutations and METgene exon 14 deletions (METex14). Clinical trial data show that evantumumab has achieved significant efficacy in these patients, bringing new hope for the treatment of this lung cancer subtype.

1.The therapeutic effect of EGFRgene mutated non-small cell lung cancer:

EGFR gene mutations are a common molecular abnormality in NSCLC that can lead to uncontrolled cell proliferation and tumor growth. Traditional EGFR inhibitors usually have good efficacy in the early stages of treatment, but over time, tumors often develop drug resistance. Evantumumab provides a new therapeutic strategy by simultaneously targeting the EGFR and MET signaling pathways.

According to clinical trial data, evantumumab has shown significant efficacy in patients with EGFR gene mutationsNSCLC. A key study is the PROMISE (NCT02716116) trial, a multicenter, open-label, single-arm clinical trial of EGFR-mutant NSCLC. In this trial, patients were treated with evantumumab, which resulted in tumor responses, including partial or complete responses, and in some patients, the treatment effects were longer-lasting. This is particularly important for patients who have previously received an EGFR inhibitor but developed resistance.

2.The therapeutic effect of METex14 deletion non-small cell lung cancer:

METex14deletion is another rare but important molecular abnormality in NSCLC. It causes abnormal activation of the MET signaling pathway and promotes tumor growth and spread. In the past, treatment options for METex14 deletionNSCLC were relatively limited. The targeting mechanism of evantumumab makes it a potentially effective treatment option.

In the OAK (NCT02609776) trial, researchers evaluated evantumumab in patients with METex14 deletionNSCLC. Trial results show that evantumumab treatment can lead to tumor remission, including partial or complete remission, and in some patients, the treatment effect is long-lasting. This provides new treatment options for patients with METex14 deletion NSCLC, especially those who have not previously benefited from traditional treatments.

3. Advantages and prospects of evantumumab:

The targeting mechanism of evantumumab acts on both the EGFR and MET signaling pathways, which is EGFR span>Gene mutations and METex14 deletions provide new treatment options for patients with NSCLC. The unique properties of this bispecific antibody allow it to inhibit the abnormal activity of two key molecules, slowing tumor growth and spread while reducing the risk of drug resistance.

In addition, clinical trial results of evantumumab show that it has good efficacy in the early stage of treatment and can prolong the duration of efficacy in some patients. This is important for lung cancer patients because long-term treatment effects are often a sign of successful treatment.

While the efficacy data for evantumumab are encouraging, it is important to note that different patients may respond differently to treatment and may experience varying degrees of adverse effects. Therefore, when using evantumumab, doctors need to develop a personalized treatment plan based on the patient's specific situation and closely monitor treatment effects and adverse reactions.

In short, evantumumab is EGFRgene mutant and METex14deletionNSCLCPatients with NSCLC are provided with a potential targeted therapy option, and its clinical trial data show its significant efficacy, bringing new hope to these patients. However, further research is needed to more fully understand its efficacy, safety, and optimal use. Patients should actively work with their doctors to determine the most appropriate treatment options to improve survival and quality of life.

Evantuzumab is not yet available in China, so patients cannot purchase it domestically and need to purchase it through foreign channels. There are only European versions of original drugs available abroad, and the price is relatively high, around 20,000 yuan.